Education
About Us
Working with TipRanks
Follow Us
TrivarX Limited (AU:TRI)
ASX:TRI
TRI Stock Chart & Stats
AU$0.02
<AU$0.01(6.67%)
At close: 4:00 PM EST
AU$0.02
<AU$0.01(6.67%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.04
Previous CloseN/A
Volume87.40K
Average Volume (3M)1.22M
Market Cap
AU$26.53M
Enterprise ValueAU$27.19M
Total Cash (Recent Filing)AU$1.25M
Total Debt (Recent Filing)AU$169.03K
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Feb 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,153,693,500
10 Day Avg. Volume1,871,965
30 Day Avg. Volume1,217,195
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-54.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthVery low leverage and a sizeable equity base provide financial flexibility, lowering insolvency risk and enabling the company to fund operations or strategic initiatives without immediate external financing. This durable balance-sheet strength supports survival while revenue is developed.
Asset & Capital BaseRising total assets and a sizeable equity base mean the company has tangible resources to support R&D, partnerships, or product development. An expanding asset base can underwrite strategic investments that drive future revenue, giving management time to execute.
Improving Cash/Loss ProfileThe company narrowed losses and sharply reduced free cash outflow in 2025 versus 2024, indicating improving operational efficiency. A sustained trend toward positive cash flow would validate cost discipline and increase runway without new capital, strengthening long-term viability.
Bears Say
No Reported RevenueZero reported revenue across the last two annual periods means the company lacks demonstrated product-market fit and has no recurring revenue base to cover fixed costs. This makes margin recovery and sustainable profitability dependent on future commercialisation success.
Persistent LossesConsecutive net losses and a sizeable operating loss reflect an unprofitable core business. Persistent negative returns on equity erode shareholder capital, requiring either a material change in business model, significant revenue scaling, or ongoing external funding to avoid dilution.
Negative Cash GenerationNegative operating cash flow and recurring free cash outflows show the company consumes cash to operate. This shortfall shortens runway and forces dependence on external financing, which can dilute shareholders or restrict strategic choices if cash generation doesn't improve.
TrivarX Limited News
TRI FAQ
What was TrivarX Limited’s price range in the past 12 months?
TrivarX Limited lowest share price was <AU$0.01 and its highest was AU$0.04 in the past 12 months.
What is TrivarX Limited’s market cap?
TrivarX Limited’s market cap is AU$26.53M.
When is TrivarX Limited’s upcoming earnings report date?
TrivarX Limited’s upcoming earnings report date is Feb 27, 2026 which is in 4 days.
How were TrivarX Limited’s earnings last quarter?
TrivarX Limited released its earnings results on Aug 28, 2025. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is TrivarX Limited overvalued?
According to Wall Street analysts TrivarX Limited’s price is currently Overvalued.
Does TrivarX Limited pay dividends?
TrivarX Limited does not currently pay dividends.
What is TrivarX Limited’s EPS estimate?
TrivarX Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TrivarX Limited have?
TrivarX Limited has 1,153,693,500 shares outstanding.
What happened to TrivarX Limited’s price movement after its last earnings report?
TrivarX Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of TrivarX Limited?
Currently, no hedge funds are holding shares in AU:TRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TrivarX Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:TRI Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$140.0K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-8.06%
Trailing 12-Months
Asset Growth
19.55%
Trailing 12-Months
Company Description
TrivarX Limited
TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023. TrivarX Limited was incorporated in 1987 and is based in Mount Lawley, Australia.
Technical Analysis
Tali Digital
―
Global Health Limited
―
Opyl Ltd.
―
HitIQ Limited
―
InteliCare Holdings Limited
―
Options Prices
Currently, No data available
---